おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Tigris Pharmaceuticals
About
Tigris Pharmaceuticals is a biopharmaceutical company developing therapeutic technologies for cancer and other unmet medical needs.
- 1 - 10
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $16M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2005
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 28, 2010 | Series C | $6.50M | 1 | — | — | Detail |
| Jan 17, 2007 | Series B | $16M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Riverbank Capital Securities
|
— | Series C |
